Skip to main content

Table 1 Effect of PFD on the secretion of cytokines and chemokines from SpA FLSs

From: The antifibrotic drug pirfenidone inhibits spondyloarthritis fibroblast-like synoviocytes and osteoblasts in vitro

Cytokine/chemokine Fold decrease
IGFBP-3 3.64
MCP-3 2.88
YKL-40 2.32
IL-8 1.30
MIG 1.27
MCP-1 1.23
Serpin E1 1.21
IL-6 1.13
IP-10 1.08
RANTES 1.04
Trombospondin-1 1.02
ICAM-1 1.02
  1. Using Image StudioTM 4.0 (LI-COR Biosciences UK Ltd) the average pixel density of the duplicate spots was determined along with the three pairs of reference spots on each array. The fold decrease is the ratio of the value of untreated cells divided by the value of pirfenidone treated cells (n = 1). IGFBP-3; Insulin-like growth factor-binding protein 3. MCP-3; monocyte-specific chemokine 3 (also called chemokine (C-C motif) ligand 7 (CCL7)). YKL-40 (also called chitinase-3-like protein 1 (CHI3L1)). MIG; monokine induced by gamma interferon (also called chemokine (C-X-C motif) ligand 9 (CXCL9)). Serpin E1 (also called plasminogen activator inhibitor-1 (PAI-1)). IP-10; interferon gamma-induced protein 10 (also called C-X-C motif chemokine 10 (CXCL10)). RANTES; regulated on activation, normal T cell expressed and secreted (also called chemokine (C-C motif) ligand 5 (CCL5)). ICAM-1; Intercellular Adhesion Molecule 1. Bold text and numbers indicate fold change > 2. Italic text and numbers indicate validation with ELISA